Hemophilia Clinical Trials

A listing of Hemophilia medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

Los Angeles California 90027

A clinical trial to evaluate treatments using MOD-5014 for patients with Hemophilia A or Hemophilia B

San Diego California 92122

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

District of Columbia

Washington District of Columbia 20010

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Florida

University of South Florida- Morsani Center for Advanced Healthcare
Tampa Florida 33612

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

View More ▼

St. Petersburg Florida 33701

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Tampa Florida 33607

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Georgia

Atlanta Georgia 30322

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Illinois

Peoria Illinois 61615

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Indiana

Indianapolis Indiana 46260

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Maine

Scarborough Maine 04074

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Maryland

Baltimore Maryland 21205

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

St. Louis Maryland 63104

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Massachusetts

Boston Massachusetts 02115

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Michigan

East Lansing Michigan 48823

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

East Lansing Michigan 48823

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Minnesota

Minneapolis Minnesota 55404

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Nevada

Las Vegas Nevada 89109

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

New Hampshire

Lebanon New Hampshire 03756

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

New York

Rochester New York 14621

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Ohio

Columbus Ohio 43205

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Oregon

Portland Oregon 97239

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Pennsylvania

UPDATED

Pittsburgh Pennsylvania

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Pittsburgh Pennsylvania 15213

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Texas

Dallas Texas 75235

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Wisconsin

Milwaukee Wisconsin 53201

Patients are needed to participate in a clinical research study of Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013 and Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013 to evaluate Hemophilia

Bulgaria

UPDATED

Plovdiv

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

UPDATED

Sofia

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

UPDATED

Varna

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

Russian Federation

UPDATED

Kirov

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

UPDATED

Moscow

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

Switzerland

UPDATED

Zurich

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

United Kingdom

UPDATED

Basingstoke

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

UPDATED

Glasgow

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

UPDATED

London SW17 0QT

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

UPDATED

London NW3 2QG

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

UPDATED

Truro

A clinical trial to evaluate treatments using ALN-AT3SC for patients with Moderate or Severe Hemophilia A or Hemophilia B

Canada

Toronto Ontario M5G 1X8

A clinical trial seeking patients for a research study for the treatment of Hemophilia or Hemophilic Arthropathy

Ireland

Dublin

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Italy

Bologna Emilia Romagna 40138

Patients are needed to participate in a clinical research study evaluating TGA (Thrombin generation Assay) for the treatment of Severe Hemophilia A With Inhibitor

Cosenza Calabria 87100

Patients are needed to participate in a clinical research study evaluating TGA (Thrombin generation Assay) for the treatment of Severe Hemophilia A With Inhibitor

Florance 50139

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Florence Tuscany 50134

Patients are needed to participate in a clinical research study evaluating TGA (Thrombin generation Assay) for the treatment of Severe Hemophilia A With Inhibitor

Genova 16148

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

View More ▼

Milan 20122

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Padova 35128

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A

Padua Veneto 35128

Patients are needed to participate in a clinical research study evaluating TGA (Thrombin generation Assay) for the treatment of Severe Hemophilia A With Inhibitor

Palermo

Patients are needed to participate in a clinical research study evaluating TGA (Thrombin generation Assay) for the treatment of Severe Hemophilia A With Inhibitor

Rome 161

A clinical research study of BIIB031 (rFVIIIFc) for the treatment of Hemophilia A, Severe Hemophilia A